title: Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft.
authors.affiliation: Centro Nacional de Investigaciones Oncologicas, Madrid, Spain.
authors.forename: M Pia
authors.initials: MP
authors.lastname: Morelli
authors.forename: Emiliano
authors.initials: E
authors.lastname: Calvo
authors.forename: Esther
authors.initials: E
authors.lastname: Ordoñez
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Wick
authors.forename: Belen-Rubio
authors.initials: BR
authors.lastname: Viqueira
authors.forename: Pedro P
authors.initials: PP
authors.lastname: Lopez-Casas
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Bruckheimer
authors.forename: Antonio
authors.initials: A
authors.lastname: Calles-Blanco
authors.forename: David
authors.initials: D
authors.lastname: Sidransky
authors.forename: Manuel
authors.initials: M
authors.lastname: Hidalgo
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000473:pathology / Q000556:secondary; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy* / Q000473:pathology*; D017321:Clinical Trials, Phase I as Topic / Q000379:methods*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D057285:Precision Medicine / Q000379:methods*; D052999:Quinazolinones / Q000008:administration & dosage; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D016756:Immunoglobulins, Intravenous; D052999:Quinazolinones; C525726:dacomitinib; C525021:figitumumab